Brind.
From Roche ends Huntington's drug program with Ionis Pharmaceuticals

How could Roche terminating Ionis's Huntington's drug program affect Alnylam Pharmaceuticals?

Possible What happens if… A possibility worth considering, not a forecast.

Ionis's setbacks may improve Alnylam's competitive position in gene-silencing. The termination of the Huntington's drug program by Roche is one of several clinical setbacks experienced by Ionis Pharmaceuticals. These disappointing late-stage results, which also included the failure of eplontersen announced by AstraZeneca, could potentially work to the benefit of Alnylam Pharmaceuticals' late-stage candidate, nucresiran. This shift in competitive dynamics could improve Alnylam's standing in the gene-silencing market.

Reported by 1 independent outlet Written Sunday
Effect
Mild positive
How direct
Stated in the reporting
When
Within weeks
The story
No new developments lately

How it reaches Alnylam Pharmaceuticals

Reported by news outlets

Tap any step to see the evidence behind it.

The facts so far

As reported. Each one links to where it comes from.

  • Roche threw in the towel on a Huntington's disease drug developed by Ionis.fool.com
  • Ionis experienced two clinical setbacks on July 9, 2026: Eplontersen failed to meet its primary endpoint in a Phase 3 study for treating transthyretin amyloid cardiomyopathy (ATTR-CM), while Roche terminated the Huntington's drug program.fool.com
  • The disappointing late-stage results announced by AstraZeneca and Ionis for eplontersen could work to the benefit of Alnylam's late-stage candidate, nucresiran.fool.com

Why it matters

The pharmaceutical market is highly sensitive to clinical trial outcomes and partnership stability. For Alnylam Pharmaceuticals, which is competing in the gene-silencing space, the failure of key rivals like Ionis Pharmaceuticals can alter the competitive landscape and potentially enhance the perceived value of its own pipeline, such as nucresiran.

This event occurs amid broader market scrutiny for biotech companies, as both Alnylam and Ionis have experienced significant bad news in 2026. Ionis's revenue declined by roughly 41% year over year in the second quarter of 2026, while Alnylam's revenue soared 74% year over year in its latest quarter.

What we don't know yet

  • How will the market specifically price in the potential competitive benefit for Alnylam Pharmaceuticals?
  • What is the current stage of Alnylam Pharmaceuticals' late-stage candidate, nucresiran?

What would change this answer

Alnylam Pharmaceuticals announces positive data for nucresiranThe potential competitive benefit would become more certain and stronger, accelerating the positive effect.
Ionis Pharmaceuticals secures a new major partnershipThe market uncertainty would lessen, and the potential benefit to Alnylam Pharmaceuticals would fade.

— Other considerations

Beyond this explainer

Questions worth asking

Ideas the web ties closely to this story that the explainer doesn't mention. These are prompts for your own research: Brind hasn't answered them.

  • About Phase III Study

    Since Eplontersen failed to meet its primary endpoint in a Phase 3 study, what specific biological mechanism was implicated in that failure?

    Explore Phase III Study
  • About Biogen

    How are Biogen's current gene-silencing pipeline candidates positioned relative to Alnylam's nucresiran?

    Explore Biogen

Explore connected ideas

Each opens a map of what the web connects to it, with Brind's news on it.

Phase III StudyBiogenAlnylam PharmaceuticalsIonis Pharmaceuticals

The ideas come from how millions of web pages place them near each other. The questions are Brind's AI reasoning, written only from this explainer and Brind's own reporting.

Who else could feel it

Other possible ripples from the same event.

Reporting

Keep going

The full eventRoche ends Huntington's drug program with Ionis Pharmaceuticals Everything aboutAlnylam Pharmaceuticals

Brind's analysis is written by AI from the reporting linked above and can be wrong. This explainer is a possibility worth considering, not a forecast: steps marked as Brind's reasoning are not stated in the reporting. It is not investment advice; do your own research.